Lauren Mifflin

Lauren Mifflin is a dedicated professional currently serving as a Fellow at 5AM Ventures, with a primary focus on developing new therapies for neurodegenerative diseases within early-stage life sciences companies.

In addition to her role at 5AM Ventures, Lauren is pursuing her graduate studies at Harvard Medical School with a specialization in neuroinflammation and neurodegeneration.

Her educational background is extensive and includes a Doctor of Philosophy (PhD) in Biological and Biomedical Sciences from Harvard University, a Master of Medical Sciences (MMSc) in Immunology from Harvard Medical School, a Master of Business Administration (MBA) in Entrepreneurship & Finance from The University of Chicago Booth School of Business, a Bachelor of Science (BSc) in Economics with a Concentration in Health Care Management from The Wharton School, and a Bachelor of Arts (BA) in Neurobiology with a Minor in Chemistry from the University of Pennsylvania.

Lauren has held various key positions in prestigious organizations, such as Chief Operating Officer at Hillstar Bio, Vice President of Company Creation at Frazier Life Sciences, Co-Founder and Founding CBO at Ypsilon Therapeutics, Venture Partner at 82VS, Senior Scientist and ALS Biology Lead at Nido Biosciences, 4:59 Operating Associate at 5AM Ventures, Fellow at Entrada Therapeutics, Fellow at 5AM Ventures, Associate at Jump Capital, Consultant at Monitor Deloitte & Monitor Group, Analyst at Insight Strategy Advisors, and Pre-Clinical Neuroscience Discovery Research Intern at sanofi-aventis.